TrialThe oncologist2019

Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.

Ai-Ping Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.